MedTrace Logo

Nexium Study To Suppress Nausea During Chemotherapy

NCT00206440 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2018-12-06

Study results available
· View outcomes & findings →

Summary

This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy.

Conditions

Interventions

DRUG

esomeprazole

nexium

OTHER

Placebo

Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Baylor Breast Care Center

    lead OTHER

Principal Investigators

  • Mothaffar Rimawi, MD · Baylor Breast Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2009-02-28
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206440 on ClinicalTrials.gov